A cath lab team at Royal Papworth Hospital has performed the UK’s first AF ablation using a new type of technology, called FARAPULSE, designed to improve safety and efficiency.
A cath lab team at Royal Papworth Hospital has performed the UK’s first ablation procedure using innovative technology designed to improve safety and efficiency.
Atrial fibrillation (AF) is the most common heart rhythm disturbance, affecting around 1.4 million people in the UK. It causes debilitating and life limiting symptoms such as palpitations, breathlessness and fatigue.
Until now, catheter ablations to treat AF have mostly used thermal energy, by either burning or freezing problematic heart tissue.
However, this carries a risk of damaging neighbouring tissue such as the oesphagus or the phrenic nerve which controls the diaphragm.
The team which performed the UK’s first pulsed field ablation on Monday 13 June was led by consultant cardiologists Dr Claire Martin, Dr Patrick Heck and Dr David Begley, supported by nurses, cardiac physiologists and radiographers.
“This technology marks a step-change in electrophysiology and may well be the future of treating atrial fibrillation with catheter ablations,” said Dr Martin.
“I am very proud of the team for making Royal Papworth Hospital the first centre in the UK to offer this technology to benefit our AF patients from across the East of England, and would like to thank everyone involved for their hard work in making it happen.”
Early studies from Europe have shown excellent outcomes and low complication rates using this new system.
Royal Papworth will also be the lead centre in the UK for the upcoming Advantage-AF research trial which will collect further data on the effectiveness of this technique.